Ifp Advisors, Inc Chimerix Inc Transaction History

Ifp Advisors, Inc

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Sep 06, 2022	BUY	$1.34 - $5.34 $134 - $534	100 New	100 $1,000
Q2 2022 Aug 12, 2022	SELL	$1.34 - $5.34 $134 - $534	-100 Closed	0 $0
Q1 2022 Sep 06, 2022	BUY	$4.58 - $6.8 $458 - $680	100 New	100 $0
Q3 2021 Oct 06, 2021	SELL	$5.94 - $8.75 $0 - $0	0 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$7.54 - $9.79 $0 - $0	0 New	0 $0
Q1 2021 Apr 30, 2021	BUY	$4.76 - $11.25 $0 - $0	0 New	0 $0
Q4 2020 Jan 25, 2021	BUY	$2.43 - $5.42 $0 - $0	0 New	0 $0
Q3 2020 Oct 29, 2020	BUY	$2.3 - $3.72 $0 - $0	0 New	0 $0
Q2 2020 Aug 05, 2020	BUY	$1.33 - $3.63 $0 - $0	0 New	0 $0
Q1 2020 May 12, 2020	BUY	$1.27 - $2.33 $0 - $0	0 New	0 $0
Q4 2019 Jan 17, 2020	BUY	$1.3 - $2.72 $0 - $0	0 New	0 $0
Q3 2019 Nov 07, 2019	BUY	$1.93 - $4.21 $0 - $0	0 New	0 $0
Q3 2018 Oct 25, 2018	SELL	$3.58 - $4.9 $780 - $1,068	-218 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$4.43 - $5.14 $965 - $1,120	218 New	218 $0
Q4 2017 Jan 24, 2018	SELL	$4.32 - $5.52 $1,188 - $1,517	-275 Closed	0 $0
Q4 2016 Jun 03, 2019	BUY	N/A	175 Added 175.0%	275 $1,000
Q2 2016 Jun 03, 2019	BUY	N/A	100	100 $0

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.